The Illusion of Certainty: How Flawed Data Skews Medical Device Markets

JERSEY CITY, N.J. – September 03, 2026 – In the high-stakes world of medical technology, data is currency. For a company planning to enter a new market or an investor vetting a potential acquisition, the public registration database of a national health authority seems like a goldmine—a direct map of the competitive landscape. A quick download, a sort by product category, and a simple row count can appear to reveal market size, key players, and compliance gaps. But a groundbreaking new analysis suggests this map is dangerously misleading.

A report published today by the regulatory consulting firm Pure Global, titled Medical Device Registration Verification 2026, systematically dismantles the assumptions that underpin many strategic decisions in the industry. After analyzing public data files from 15 national jurisdictions, the firm's central finding is both simple and profound: a public register is not a market map. The raw numbers that teams rely on are often distorted by inconsistent data structures, critical information gaps, and fundamental misunderstandings of what a database truly represents. The result is a landscape of flawed market sizing, wasted due-diligence hours, and missed opportunities, all stemming from the illusion that a spreadsheet row equals a product on the market.

The Anatomy of a Miscalculation

The core of the problem lies in a concept the report calls file "grain"—essentially, what a single row in a data file actually represents. Without understanding this, comparison is not just difficult; it's deceptive. The analysis provides stark examples of how this plays out across the globe.

In Ecuador, the national catastro, or register, boasts an impressive 254,292 rows. A superficial glance might suggest a massive, bustling market. But the reality, uncovered by the study, is that these rows correspond to only 23,198 distinct registration numbers. Here, the grain is not a unique product registration but a catalog item, with each certificate covering, on average, eleven different items or models. A market thought to be ten times larger than it is can lead to catastrophic miscalculations in resource allocation.

This is not an isolated issue. Canada’s Medical Device Active Licence Listing (MDALL) contains over 153,000 device identifiers, but these are consolidated under just 35,387 licenses—a ratio of more than four to one. Across the Pacific, Singapore's database appears refreshingly straightforward, with an almost one-to-one ratio of rows to registration numbers. Yet this apparent clarity hides a crucial omission: the register completely excludes Class A devices, the lowest-risk category. Those products, which can represent a significant market segment, are tracked in an entirely separate database, invisible to anyone who doesn't know where to look.

"Row counts are records, not installed base—and a missing name match is not an illegal product," warned Ran Chen, Chief Technology Officer at Pure Global, in the press release. "Before anyone treats a public file as evidence, they have to name what one row actually is: a certificate, a catalog item, a decision record or a document crawl. That single step prevents most of the verification errors we see."

More Than Just Missing Numbers

Beyond the structural issue of file grain, the analysis reveals alarming gaps in data completeness. For a company trying to understand its competitive positioning, knowing the risk class of a rival's device or the manufacturer's country of origin is vital. Yet, of the ten national files audited in depth, risk classification was populated in only five. Manufacturer country was complete in just three.

Even more striking, the United Arab Emirates' EDE file, containing 4,740 rows of device data, had zero registration numbers populated, making it impossible to verify a product's status against an official certificate. The data is present, but the key to unlocking its meaning is missing.

This problem extends to the industry's most relied-upon databases. The U.S. FDA’s 510(k) database, with its 175,000+ records, is frequently treated as a list of currently marketed products. It is not. It is a historical archive of clearance decisions, stretching back decades, many for devices that are no longer sold. Similarly, Europe’s much-anticipated EUDAMED database, which became mandatory for new device registrations earlier this year, is still a work in progress. The report found that of the 2.9 million device models logged, the field for the authorized representative—a legally required entity—was filled in less than half the time (48.5%). This aligns with broader industry chatter about the immense data governance challenges manufacturers face in populating the complex system correctly.

"We see it constantly," commented one independent regulatory consultant who was not involved in the study. "A team will see a competitor isn't in EUDAMED and assume they aren't compliant, but the reality might be that it's a legacy device with a later registration deadline. Treating these databases as definitive, real-time registers is a rookie mistake with senior-level consequences."

The Real-World Costs of a Flawed Map

The consequences of misreading these digital tea leaves are tangible and costly. They manifest as wasted hours, flawed strategies, and compliance emergencies that can halt a product launch in its tracks. One business development executive at a mid-sized diagnostics firm shared an experience, speaking on the condition of anonymity.

"We spent the better part of a quarter on due diligence for a potential distribution partner in Latin America," he explained. "Our initial search of the public database suggested their flagship product wasn't registered. We nearly killed the deal. It turned out the registration was held under a slightly different legal entity name. The data wasn't wrong, but our interpretation was. The file's grain was at the certificate level, not the product-name level. We wasted thousands of dollars and nearly lost a key partner because we didn't know how to read the map."

This story is a common one. Market-sizing reports built on inflated row counts can lead investors to pour money into saturated sectors. Conversely, a device that is validly registered can be mistaken for non-compliant, leading to baseless accusations and damaged partnerships. Perhaps most critically, a flawed reading can cause a company to miss that it still needs to appoint a local representative or in-country sponsor, a discovery often made just as the first shipment is waiting at customs, triggering costly delays and regulatory penalties.

A New Playbook for a Fragmented World

In response to this systemic challenge, the Pure Global analysis proposes a nine-step verification sequence. It's less a simple checklist and more a fundamental shift in methodology—a move from passive data consumption to active, critical intelligence gathering. The playbook insists that teams must first name the unit being counted, identify each file's specific grain, and lock onto stable identity fields like registration numbers before attempting any name-based matching.

Crucially, it advises treating name searches as preliminary clues, not conclusions, and always reading a device's status and expiration date at the correct grain (e.g., at the certificate level, not the individual catalog item level). It also formalizes the need to seek out sister databases for excluded product classes and to keep archival sources like the FDA 510(k) file in a separate reference folder, distinct from live market registers. This disciplined approach transforms a verification task from a simple search into a small-scale forensic investigation.

The Unseen Push for Harmonization

The issues highlighted in the report are symptoms of a larger, global condition: regulatory fragmentation. While every nation rightly maintains sovereignty over its health system, the resulting patchwork of rules and data structures creates immense friction for the globalized MedTech industry. However, slow-moving efforts are underway to address this.

The mandatory rollout of EUDAMED in Europe, despite its teething problems, represents a monumental push toward a standardized, transparent system. It is forcing companies, many for the first time, to confront deep-seated issues in their own data governance. In the U.S., the FDA's recent alignment of its quality system regulations with the international ISO 13495 standard is another step toward a common language.

Initiatives like Unique Device Identification (UDI) were conceived to be the ultimate solution—a single, globally recognized barcode for every device. But implementation has been staggered and inconsistent across jurisdictions, meaning its promise as a universal key has yet to be fully realized. For now, the landscape remains a complex mosaic of national quirks and disparate systems. Navigating it successfully requires more than just access to data; it requires a new literacy in the art and science of regulatory interpretation.